Histone demethylase lysine demethylase 5B in development and cancer
Metrics: PDF 1655 views | HTML 3519 views | ?
Mengjiao Han1, Wenxia Xu1, Pu Cheng2, Hongchuan Jin1, Xian Wang1
1Department of Medical Oncology, Key Laboratory of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, China
2Department of Surgical Oncology, Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
Xian Wang, email: firstname.lastname@example.org
Keywords: histone methylation, demethylases, KDM5B
Received: September 12, 2016 Accepted: November 08, 2016 Published: December 10, 2016
Histone methylation is one of the most important chromatin posttranslational modifications. It has a range of influences on nuclear functions including epigenetic inheritance, transcriptional regulation and the maintenance of genome integrity. Changes in histone methylation status take part in various physiological and pathological processes. KDM5B (lysine demethylase 5B, also called JARID1B or PLU-1) encodes the histone H3 lysine4 (H3K4) demethylase and exhibits a strong transcriptional repression activity. KDM5B plays a role in cell differentiation, stem cell self-renewal and other developmental progresses. Recent studies showed that KDM5B expression was increased in breast, bladder, lung, prostate and many other tumors and promotes tumor initiation, invasion and metastasis. Given its association with tumor progression and prognosis of cancer patients, KDM5B was proposed to be a novel target for the prevention and treatment of human cancers. In this review, we will summarize recent advances in our understanding of the regulation and function of KDM5B in development and cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.